Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Lymphoid 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 13Myelodysplastic Syndromes 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Myeloproliferative Disorders 6Leukemia, Myelomonocytic, Chronic 6Congenital Abnormalities 5Lymphoma, Non-Hodgkin 4Leukemia, Myeloid, Accelerated Phase 4Leukemia 4Blast Crisis 4Anemia, Refractory, with Excess of Blasts 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Leukemia, Promyelocytic, Acute 3Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia, Erythroblastic, Acute 3Hodgkin Disease 3Thrombocythemia, Essential 2Prostatic Neoplasms 2Primary Myelofibrosis 2Polycythemia Vera 2Multiple Myeloma 2Lymphoma, Mantle-Cell 2Leukemia, Myelomonocytic, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Monocytic, Acute 2Leukemia, Hairy Cell 2

Interventions

Cyclophosphamide 10fludarabine 8Mycophenolic Acid 7Tacrolimus 6Melphalan 6ruxolitinib 5fludarabine phosphate 5Imatinib Mesylate 5Busulfan 5Bone Marrow Transplantation 5ponatinib 4Mesna 4Azacitidine 4nilotinib 3Whole-Body Irradiation 3Thiotepa 3Stem Cell Transplantation 3Granulocyte Colony-Stimulating Factor 3Cyclosporine 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3lintuzumab 2Vorinostat 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2Methotrexate 2Filgrastim 2Alemtuzumab 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2vosaroxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hematologic Diseases × Vorinostat × Myeloid × Clear all
NCT03842696 2026-01-27

Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

University of Michigan Rogel Cancer Center

Phase 1/2 Active not recruiting
43 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Graft vs Host Disease, Hematologic Diseases, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT00866762 2011-12-12

A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia

Copenhagen University Hospital at Herlev

Phase 2 Unknown
60 enrolled
Myeloid

Hematologic Diseases, Polycythemia, Polycythemia Vera, Thrombocythemia, Essential

Data powered by HemOnc (CC BY 4.0) Colophon âš¡